IRB #

STUDY00021766

Title

A Phase I/Ib Study to Evaluate the Safety, Tolerability, Biological and Clinical Activities of GEN-001 in Combination with Avelumab in Patients with Advanced Solid Tumors Who Have Progressed during or after Treatment with Anti-PD-(L)1 therapy

Principal Investigator

Shivaani Kummar

Study Purpose

The purpose of this study is to find out if the investigational drug called GEN001 is safe in people with a variety of different cancers and what effects it has on cancer.

Medical Condition(s)

advanced cancer

Eligibility Criteria

Male and Female participants of 18 years of age and older.
Diagnosed with advanced or metastatic cancer.

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

How long you participate in this study depends on side effects you may have to the study drug. It also depends on how your cancer might respond to the study drug.
If your cancer improves or stays the same and you do not have serious side effects from the study drug, you may remain in the study as long as your study doctor feels you may benefit. However, you are free to stop taking part in this study at any time and for any reason.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080
trials@ohsu.edu

Sponsor

Genome & Company

Recruitment End

06/30/2022

Compensation Provided

No


Go Back